Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
about
Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancerTargeting the stromal fibroblasts: a novel approach to melanoma therapy.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaTGF-β Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma.Targeting integrins in hepatocellular carcinoma.Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinomaThe Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins.Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.[Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic rats.
P2860
Q36285667-7B131C0F-1F37-4D47-AFAC-4FD36A71C7FAQ36334912-4C3D83D6-FE1E-4870-9BD3-25A737CE5D00Q37351498-46A8C4AB-8C91-448C-A977-B5A2B341EDADQ37705967-6E400ACE-3825-4714-9B78-F4AC63BCAAC1Q37844564-27391E52-8DB8-4A94-99F8-49EBED31B8D9Q38207013-71286808-342C-46AF-9270-D25D6D26BC1EQ38654867-C52158DF-4F21-48E5-9816-C928BE9442E6Q39635376-4313DF34-44B8-4BC1-8CD1-7E96E4A42364Q39733170-ED81B2C7-CCD2-4B27-BFBE-74648A14982FQ40065276-CB46A02B-9D43-4EBF-BFE3-856AFA028F74Q41876620-4B586C08-A74D-4B47-B3EB-0505FA3B839CQ42951192-0F3677BD-BED7-4C24-8540-7B3BEE5D72B0Q50537049-C15DA50D-2C88-4DE9-AFA5-88174C2FE644
P2860
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
@ast
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
@en
type
label
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
@ast
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
@en
prefLabel
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
@ast
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
@en
P2093
P2860
P356
P1476
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells
@en
P2093
A Paradiso
E Fransvea
L Porcelli
S Antonaci
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602231
P407
P577
2004-11-01T00:00:00Z